Verrica Pharmaceuticals Inc. (VRCA)

NCM – Цена в реальном времени. Валюта: USD

6.84

+0.63 (10.14%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

6.84

0.00 (0.00%)

После закрытия: Jun 26, 2026, 4:10 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Verrica Pharmaceuticals Inc. (VRCA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Verrica Pharmaceuticals Inc. (VRCA)

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Verrica Pharmaceuticals Q1 Earnings Call Highlights

Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcript

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Видео

No Data

Пресс-релизы

Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference

Search stocks

Verrica Pharmaceuticals Inc. (VRCA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Verrica Pharmaceuticals Inc. (VRCA)

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Verrica Pharmaceuticals Q1 Earnings Call Highlights

Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcript

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Видео

No Data

Пресс-релизы

Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference